Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Jul;62(1):54–60. doi: 10.1172/JCI109113

The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments.

G H Goldsmith Jr, H Saito, O S Ratnoff
PMCID: PMC371736  PMID: 659637

Abstract

Activation of plasminogen through surface-mediated reactions is well recognized. In the presence of kaolin, purified Hageman factor (Factor XII) changed plasminogen to plasmin, as assayed upon a synthetic amide substrate and by fibrinolysis. Kinetic studies suggested an enzymatic action of Hageman factor upon its substrate, plasminogen. Hageman factor fragments, at a protein concentration equivalent to whole Hageman factor, activated plasminogen to a lesser extent. These protein preparations were not contaminated with other agents implicated in surface-mediated fibrinolysis. Diisopropyl fluorophosphate treatment of plasminogen did not inhibit its activation by Hageman factor. These studies indicate that Hageman factor has a hitherto unsuspected function, the direct activation of plasminogen.

Full text

PDF
54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colman R. W. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun. 1969 Apr 29;35(2):273–279. doi: 10.1016/0006-291x(69)90278-2. [DOI] [PubMed] [Google Scholar]
  2. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  3. Forbes C. D., Ratnoff O. D. Studies on plasma thromboplastin antecedent (factor XI), PTA deficiency and inhibition of PTA by plasma: pharmacologic inhibitors and specific antiserum. J Lab Clin Med. 1972 Jan;79(1):113–127. [PubMed] [Google Scholar]
  4. Kaplan A. P., Austen K. F. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med. 1972 Dec 1;136(6):1378–1393. doi: 10.1084/jem.136.6.1378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kaplan A. P., Meier H. L., Mandle R., Jr The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin-generation. Semin Thromb Hemost. 1976 Jul;3(1):1–26. doi: 10.1055/s-0028-1087162. [DOI] [PubMed] [Google Scholar]
  6. Kluft C. Occurrence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis. 1976;5(3):136–146. doi: 10.1159/000214129. [DOI] [PubMed] [Google Scholar]
  7. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  8. Laake K., Venneröd A. M. Factor XII-induced fibrinolysis: studies on the separation of prekallikrein, plasminogen proactivator, and factor XI in human plasma. Thromb Res. 1974 Feb;4(2):285–302. doi: 10.1016/0049-3848(74)90093-0. [DOI] [PubMed] [Google Scholar]
  9. NIEWIAROWSKI S., PROU-WARTELLE O. [Role of the contact factor (Hageman factor) in fibrinolysis]. Thromb Diath Haemorrh. 1959 Sep 1;3:593–603. [PubMed] [Google Scholar]
  10. Ogston D., Ogston C. M., Ratnoff O. D., Forbes C. D. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest. 1969 Oct;48(10):1786–1801. doi: 10.1172/JCI106145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Plow E. F., Edgington T. S. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest. 1975 Jul;56(1):30–38. doi: 10.1172/JCI108076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. RATNOFF O. D., DAVIE E. W. The purification of activated Hageman factor (activated factor XII). Biochemistry. 1962 Nov;1:967–975. doi: 10.1021/bi00912a005. [DOI] [PubMed] [Google Scholar]
  13. Ratnoff O. D. Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI). J Lab Clin Med. 1972 Nov;80(5):704–710. [PubMed] [Google Scholar]
  14. Revak S. D., Cochrane C. G., Johnston A. R., Hugli T. E. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest. 1974 Sep;54(3):619–627. doi: 10.1172/JCI107799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. SCHOENMAKERS J. G., KURSTJENS R. M., HAANEN C., ZILLIKEN F. PURIFICATION OF ACTIVATED BOVINE HAGEMAN FACTOR. Thromb Diath Haemorrh. 1963 Jul 31;35:546–556. [PubMed] [Google Scholar]
  16. Saito H., Goldsmith G. H., Jr Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay. Blood. 1977 Sep;50(3):377–385. [PubMed] [Google Scholar]
  17. Saito H., Goldsmith G., Waldmann R. Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas. Blood. 1976 Dec;48(6):941–947. [PubMed] [Google Scholar]
  18. Saito H., Ratnoff O. D., Donaldson V. H. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circ Res. 1974 May;34(5):641–651. doi: 10.1161/01.res.34.5.641. [DOI] [PubMed] [Google Scholar]
  19. Saito H., Ratnoff O. D., Marshall J. S., Pensky J. Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin. J Clin Invest. 1973 Apr;52(4):850–861. doi: 10.1172/JCI107249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Saito H., Ratnoff O. D., Waldmann R., Abraham J. P. Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil). J Clin Invest. 1975 May;55(5):1082–1089. doi: 10.1172/JCI108009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Weiss A. S., Gallin J. I., Kaplan A. P. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest. 1974 Feb;53(2):622–633. doi: 10.1172/JCI107597. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES